ECSP17077930A - Métodos y kits para tratar la depresión - Google Patents

Métodos y kits para tratar la depresión

Info

Publication number
ECSP17077930A
ECSP17077930A ECIEPI201777930A ECPI201777930A ECSP17077930A EC SP17077930 A ECSP17077930 A EC SP17077930A EC IEPI201777930 A ECIEPI201777930 A EC IEPI201777930A EC PI201777930 A ECPI201777930 A EC PI201777930A EC SP17077930 A ECSP17077930 A EC SP17077930A
Authority
EC
Ecuador
Prior art keywords
kits
methods
treatment
depression
treat depression
Prior art date
Application number
ECIEPI201777930A
Other languages
English (en)
Spanish (es)
Inventor
Ella Daly
Wayne Drevets
Jaskaran Singh
Ivo Caers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP17077930A publication Critical patent/ECSP17077930A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ECIEPI201777930A 2015-05-20 2017-11-23 Métodos y kits para tratar la depresión ECSP17077930A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20

Publications (1)

Publication Number Publication Date
ECSP17077930A true ECSP17077930A (es) 2018-02-28

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201777930A ECSP17077930A (es) 2015-05-20 2017-11-23 Métodos y kits para tratar la depresión

Country Status (20)

Country Link
US (1) US20160338977A1 (enExample)
EP (1) EP3297618A4 (enExample)
JP (1) JP2018515557A (enExample)
KR (1) KR20180008634A (enExample)
CN (1) CN107735081A (enExample)
AU (3) AU2016263598A1 (enExample)
CA (1) CA2986477A1 (enExample)
CL (1) CL2017002904A1 (enExample)
CO (1) CO2017011564A2 (enExample)
DO (1) DOP2017000268A (enExample)
EA (1) EA201792545A1 (enExample)
EC (1) ECSP17077930A (enExample)
GT (1) GT201700246A (enExample)
HK (1) HK1252937A1 (enExample)
IL (1) IL255463A (enExample)
MA (1) MA42135A (enExample)
MX (1) MX2017014797A (enExample)
PE (1) PE20180260A1 (enExample)
PH (1) PH12017502103A1 (enExample)
WO (1) WO2016187491A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3813807A1 (en) * 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020178653A1 (en) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN114286674A (zh) * 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
KR20230018448A (ko) * 2020-05-28 2023-02-07 얀센 파마슈티카 엔.브이. 우울증의 치료 방법
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
EP2983787B1 (en) * 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
KR20170054470A (ko) * 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법

Also Published As

Publication number Publication date
US20160338977A1 (en) 2016-11-24
MX2017014797A (es) 2018-02-15
GT201700246A (es) 2019-07-29
PE20180260A1 (es) 2018-02-05
EA201792545A1 (ru) 2018-05-31
WO2016187491A1 (en) 2016-11-24
PH12017502103A1 (en) 2018-05-07
IL255463A (en) 2018-01-31
AU2016263598A1 (en) 2017-11-23
CN107735081A (zh) 2018-02-23
MA42135A (fr) 2018-03-28
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
JP2018515557A (ja) 2018-06-14
AU2021215155A1 (en) 2021-09-02
EP3297618A1 (en) 2018-03-28
KR20180008634A (ko) 2018-01-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
HK1252937A1 (zh) 2019-06-06
CL2017002904A1 (es) 2018-04-20
EP3297618A4 (en) 2019-01-23
CA2986477A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
ECSP17077930A (es) Métodos y kits para tratar la depresión
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX388325B (es) Metodos de diagnostico para tratamiento con linfocitos t.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
MX2018016332A (es) Quimioterapias de combinacion.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
CL2019000625A1 (es) Combinación de agonistas de fxr.
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131